Michael S Weiss
CIK 1038977 · Executive Vice Chairman · last filed 2026-03-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TGTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FBIOP | Executive Vice Chairman | 2,276,562 | $15.90 | $36.20M | $1.25M | 10 | 2026-03-20 |
| TGTX | CEO | 24,212,300 | $56.39 | $1.37B | -$3.35M | 23 | 2026-01-09 |
| Checkpoint Therapeutics, Inc. (CKPT) Delisted | Director | 187,007 | $4.26 | $796.6K | $0 | 9 | 2025-05-30 |
| MBIO | Director | 1,060 | $0.36 | $379 | $0 | 5 | 2023-07-07 |
| AVENUE THERAPEUTICS, INC. (ATXI) Delisted | Director | 22 | $0.35 | $8 | $0 | 1 | 2018-08-08 |
| FBIO | Exec. VC - Strategic Dev. | 533,411 | $1.93 | $1.03M | $0 | 2 | 2017-01-27 |
| Fortress Biotech, Inc. (CNDO) Delisted | Exec. VC - Strategic Dev. | 6,938,038 | — | — | $1.61M | 3 | 2014-11-10 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Chief Executive Officer | 1,465,137 | — | — | -$5.08M | 6 | 2010-05-12 |
| XTLB | Director | — | $1.78 | — | $0 | 1 | 2008-11-04 |
Recent Filings · Page 5 of 7
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-01-27 | FBIO | Grant (A) | +552,698 | $0 | EDGAR |
| 2017-01-04 | TGTX | Mixed | +690,255 | $0 | EDGAR |
| 2016-09-01 | TGTX | Gift (G) | −328,764 | $0 | EDGAR |
| 2016-01-05 | FBIO | Grant (A) | +510,434 | $0 | EDGAR |
| 2016-01-04 | TGTX | Grant (A) | +672,343 | $0 | EDGAR |
| 2016-01-04 | TGTX | Grant (A) | +6,723,443 | $0 | EDGAR |
| 2015-06-05 | TGTX | Grant (A) | +337,257 | $0 | EDGAR |
| 2015-01-02 | TGTX | Grant (A) | +268,603 | $0 | EDGAR |
| 2014-12-18 | TGTX | Sell (S) | −210,618 | -$3.46M | EDGAR |
| 2014-11-10 | Fortress Biotech, Inc. (CNDO) Delisted | Buy (P) | +1,000,000 | $1.61M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.